Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Bullboard Posts
Post by silverwolf08on Dec 12, 2017 2:58pm
149 Views
Post# 27140629

Next news and Share acquisition extension

Next news and Share acquisition extension

 

So at the end of the article it just states : “We expect to report further updates in the near future along with the final test results from our Zika testing with our TherOZap™ technology”.     

 

It sounds like test results might not be out before Christmas, as mentioned previously, but that’s fine by me. Happy to wait til January because....

 

January/February also brings the closing of a share purchase agreement. 

 

“As previously reported on Nov. 2, 2017, relating to the proposed acquisition for acne and other cosmetic applications, Jenex has agreed with the vendor of the target acquisitions to extend the execution of a definitive share purchase agreement to an anticipated closing date of Feb. 15, 2018. The proposed acquisition will be subject to customary due diligence which has been extended to Jan. 15, 2018.”
 

The Chinese Global Financial Forum was a success at generating interest, so we could have news any day about a new distribution agreement or investment. 

 

Great timeline and NR overall 

would love to see the tv interview if anyone can find it

 
Bullboard Posts